Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD) by Halberstadt, AL et al.
 
Halberstadt, AL, Chatha, M, Klein, AK, McCorvy, JD, Meyer, MR, Wagmann, L, 
Stratford, A and Brandt, SD
 Pharmacological and biotransformation studies of 1-acyl-substituted 
derivatives of d-lysergic acid diethylamide (LSD)
http://researchonline.ljmu.ac.uk/id/eprint/11815/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Halberstadt, AL, Chatha, M, Klein, AK, McCorvy, JD, Meyer, MR, Wagmann, 
L, Stratford, A and Brandt, SD (2019) Pharmacological and 
biotransformation studies of 1-acyl-substituted derivatives of d-lysergic 
acid diethylamide (LSD). Neuropharmacology, 127. ISSN 0028-3908 
LJMU Research Online
 
Pharmacological and biotransformation studies of 1-acyl-substituted 
derivatives of d-lysergic acid diethylamide (LSD) 
 
 
Adam L. Halberstadt,1,2 Muhammad Chatha,1 Adam K. Klein,1 John D. McCorvy,3  




1 Department of Psychiatry, University of California San Diego, La Jolla, CA 92093-0804, USA 
 
2 Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA 
92161, USA 
 
3 Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, 
Milwaukee, Wisconsin, USA 
 
4 Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical 
Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, 
66421 Homburg, Germany 
 
5 Synex Synthetics BV, Karveelweg 20, 6222NH, Maastricht, The Netherlands 
 
6 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom 
Street, Liverpool L3 3AF, UK 
 
 
Pages: 20; Figures: 4, Tables: 7 
 
 
* Correspondence to: Adam L. Halberstadt, Department of Psychiatry, University of California 
San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0804 USA. E-Mail: ahalberstadt@ucsd.edu 
 
 
Running title: Pharmacological characterization of 1-acyl lysergamides 
 
Declarations of interest: none 
 
Keywords: New psychoactive substances; LSD; 5-HT2A receptor; lysergamides; psychedelics 
Neuropharmacology - November 2019 (accepted, uncorrected)
ABSTRACT 
 
The ergoline d-lysergic acid diethylamide (LSD) is one of the most potent psychedelic drugs.  1-
Acetyl-LSD (ALD-52), a derivative of LSD containing an acetyl group on the indole nitrogen, 
also produces psychedelic effects in humans and has about the same potency as LSD.  Recently, 
several other 1-acyl-substitued LSD derivatives, including 1-propanoyl-LSD (1P-LSD) and 1-
butanoyl-LSD (1B-LSD), have appeared as designer drugs.  Although these compounds are 
assumed to act as prodrugs for LSD, studies have not specifically tested this prediction.  The 
present investigation was conducted to address the gap of information about the pharmacological 
effects and mechanism-of-action of 1-acyl-substituted LSD derivatives.  Competitive binding 
studies and calcium mobilization assays were performed to assess the interaction of ALD-52, 1P-
LSD, and 1B-LSD with serotonin 5-HT2
performed with 1B-LSD to assess its binding to othe
(HTR) studies were performed in C57BL/6J mice to assess in vivo activation of 5-HT2A (the 
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1. INTRODUCTION 
 
 The psychedelic (hallucinogenic) effects of d-lysergic acid diethylamide (LSD, Fig. 1) 
were discovered serendipitously by Dr. Albert Hofmann in 1943 (Hofmann 1979,1980).  LSD is 
active at p.o. doses ranging from 60–200 µg (Shulgin and Shulgin 1997), making it a highly 
potent compound.  The finding that minute doses of LSD can produce profound changes in 
consciousness inspired research across multiple disciplines and helped to launch the modern era 
of biological psychiatry.  During the 1950s and 1960s, hundreds of clinical studies were 
conducted with LSD.  Reports appeared indicating LSD may possess therapeutic efficacy in 
disorders such as depression, alcoholism, and chronic pain (Kast and Collins 1964; Pahnke et al. 
1969; Krebs and Johansen 2012).  By the early 1970s, however, most clinical work with LSD 
had ceased due to legal restrictions.  Human trials have cautiously resumed in recent years to 
investigate the therapeutic efficacy of LSD and to explore its potential as a tool for neuroscience 
research (Gasser et al. 2015; Kraehenmann et al. 2017b; Müller et al. 2017; Preller et al. 2017; 
Preller et al. 2018b; Schmidt et al. 2018).  In addition to its use in scientific studies, LSD was 
closely associated with the counterculture during the 1960s and it continues to be a popular 
recreational drug. 
 In addition to LSD, many other lysergamides have been synthesized in order to define the 
structure-activity relationships for this class of compounds (Nichols 2018).  Various substitutions 
were made on the indole nitrogen (position N1) of LSD, including the attachment of acyl groups. 
One of the earliest examples is 1 acetyl LSD (ALD 52, Fig. 1).  The preparation of ALD-52 
was first reported by Troxler and Hofmann in 1957 (Troxler and Hofmann 1957).  Tests of ALD-
52 in human subjects revealed that it produces LSD-like effects and closely matches the time-
course of LSD (Rothlin 1957; Abramson 1959; Isbell et al. 1959; Malitz et al. 1960).  According 
to Rothlin (1957), both LSD and ALD-52 are active at doses of 0.5–1 µg/kg, but further 
experimental details were not provided.  Abramson (1959) found ALD-52 to be 91% as potent as 
LSD, whereas Isbell et al. (1959) reported that the two substances are equipotent.  In another 
study conducted in normal subjects and psychotic patients, LSD and ALD-52 produced similar 
effects, but the latter compound seemed to alter cognition and body image to a greater extent 
than LSD (Malitz et al. 1960).  Although claims have been made that some of the LSD 
distributed during the late 1960s was actually ALD-52 (Tendler and May 1984), the first 
confirmed detection of the drug on the illicit market occurred in April 2016 (EMCDDA 2018).     
Similar to ALD-52, other N1-acyl-substituted ergoline derivatives have been marketed 
online as recreational drugs.  1 Propanoyl LSD (1P LSD, Fig. 1) was first detected in 2015 
(Brandt et al. 2016; EMCDDA 2018).  1-Butanoyl (1B-LSD) and 1-propanoyl-6-ethyl-6-nor-
LSD (1P ETH LAD) have also appeared on the recreational drug market (Brandt et al. 2017b; 
Brandt et al. 2019).  Notably, as far as we are aware, 1P-LSD, 1B-LSD, and 1P-ETH-LSD had 
not been reported in the scientific or patent literature prior to their appearance as recreational 
substances, making them true “designer drugs.” 
 It is not clear whether ALD-52 and its homologues are the active pharmacological 
species, or alternatively whether they serve as prodrugs for LSD.  According to recent studies, 
the psychedelic effects of LSD in humans are largely attributable to 5-HT2A receptor activation 
(Barrett et al. 2017; Kraehenmann et al. 2017a; Kraehenmann et al. 2017b; Preller et al. 2017; 
Preller et al. 2018a).  Although little is known about the pharmacological properties of ALD-52 
and its homologues, substitution on the indole nitrogen typically reduces the affinity of ergolines 
for the human 5-HT2A (h5-HT2A) receptor by 20–30-fold (Johnson et al. 1994).  For example, the 
N1-unsubstituted lysergamide LY193525 has sub-nanomolar affinity for the human 5-HT2A 
receptor (Ki = 0.73 nM vs. [3H]ketanserin), whereas its N1-isopropyl derivative amersergide has 
~20-fold lower affinity (Ki = 16.2 nM) (Johnson et al. 1994).  According to mutagenesis 
experiments and molecular modeling studies, when tryptamines and ergolines bind to h5-HT2A, 
the indole N1 hydrogen interacts with residue 5.46 for agonist activation (McCorvy et al. 2018), 
and specifically with S2425.46 in the human 5-HT2A receptor (Nelson et al. 1993; Johnson et al. 
1994; Almaula et al. 1996).  Although studies to date have not characterized the 
biotransformation of ALD-52, 1P-LSD, or 1B-LSD in vivo, ergolines containing a methyl group 
on the indole nitrogen are metabolized by N-dealkylation (Enz et al. 1984; Tfelt-Hansen et al. 
1985; Bredberg et al. 1986; Muller-Schweinitzer and Tapparelli 1986; Bredberg and Paalzow 
1990).  Experiments have confirmed that enzymes present in human serum and liver can 
deacylate ALD-52, 1P-LSD, 1B-LSD, and 1P-ETH-LAD (Brandt et al. 2016; Wagmann et al. 
2019).  A recent intoxication case involving 1P-LSD indicated formation of LSD in vivo with no 
detection of the parent molecule (Grumann et al. 2019).  Similar to ALD-52, 1P-LSD and 1B-
LSD also have about the same potency as LSD in humans, which is another factor indicating that 
they likely act as prodrugs.   
 Given the difficulties associated with hallucinogen studies in humans, animal behavioral 
models have been widely used to investigate the pharmacology of serotoninergic hallucinogens 
(Halberstadt 2015; Halberstadt and Geyer 2018).  LSD and other serotoninergic hallucinogens 
induce the head-twitch response (HTR), a paroxysmal side-to-side head rotation, in mice and rats 
via 5 HT2A receptor activation (Halberstadt et al. 2011; Canal and Morgan 2012).  The HTR is 
commonly used as a behavioural proxy in rodents for human hallucinogenic effects because it is 
one of only a few behaviours that can reliably distinguish hallucinogenic and non
hallucinogenic 5 HT2A receptor agonists (Gonzalez-Maeso et al. 2007; Halberstadt and Geyer 
2013).  Head twitches were traditionally assessed using direct observation but new methods have 
been developed to detect the behavior in a semi-automated fashion using a head-mounted magnet 
and a magnetometer coil (Halberstadt and Geyer 2013,2014).  The HTR serves as a behavioral 
readout of 5-HT2A activation and can be used to compare the in vivo potencies of 5-HT2A 
receptor agonists (Nichols et al. 2015; Halberstadt et al. 2016; Brandt et al. 2017a; Brandt et al. 
2018; Klein et al. 2018; Halberstadt et al. 2019b; Halberstadt et al. 2019c).  Previous studies 
performed in our laboratory demonstrated that 1P-LSD and 1B-LSD induce head twitches in 
male C57BL/6J mice with approximately one-third and one-sixth of the potency of LSD, 
respectively (Brandt et al. 2016; Brandt et al. 2019).   Surprisingly, according to Corne and 
Pickering (1967), ALD-52 does not induce head twitches in mice; however, it is difficult to 
interpret their findings due to the specific methods used in the experiments (i.e., HTR activity 
was assessed using quantal scoring).   
The present investigation was conducted to address the gap of information about the 
pharmacological effects and mechanism-of-action of 1-acyl-substituted lysergamides.  
Interactions of ALD-52, 1P-LSD, and 1B-LSD with serotonin (5 HT) receptor subtypes were 
assessed using competitive binding and functional assays.  Biotransformation studies were 
conducted to determine whether ALD-52 and 1P-LSD are metabolized to LSD after in vivo 
administration.  HTR studies were also conducted to address the conflicting findings regarding 
the activity of ALD-52 in humans and mice.  The results of these experiments support the 
prediction that the deacylation of ALD-52, 1P-LSD, and 1B-LSD to LSD likely plays a key role 
in their behavioral effects. 
2.  MATERIALS AND METHODS 
 
2.1.  Animals 
 
 Animals were housed in a vivarium at the University of California San Diego, an 
AAALAC-approved animal facility that meets all Federal and State requirements for care and 
treatment of laboratory animals.  Male C57BL/6J mice (6-8 weeks old) obtained from Jackson 
Laboratories (Bar Harbor, ME, USA) and were housed up to four per cage in a climate-
controlled room on a 12-h reverse-light cycle (lights on at 1900 h, off at 0700 h).  Male 
Hsd:Sprague Dawley rats (ENVIGO, Indianapolis, IN, USA; initial weight 230–250 g) were 
housed in pairs in a climate-controlled room on a 12-h reverse-light cycle (lights on at 1900 h, 
off at 0700 h).  Food and water were available ad libitum except during behavioral testing, which 
was conducted between 1000 and 1800 h.  Animals were acclimatized for approximately 1 week 
after arrival prior to behavioral testing and maintained in American Association for Accreditation 
of Laboratory Animal Care-approved facilities that meet all federal and state guidelines.  All 
animal experiments were carried out in accordance with NIH guidelines and were approved by 
the UCSD institutional animal care and use committee.  Principles of laboratory animal care 
were followed as well as specific laws of the USA.   
 
2.2.  Drugs and Reagents 
 
 1-Acetyl-d-lysergic acid diethylamide (ALD-52), 1-propanoyl-d-lysergic acid 
diethylamide (1P-LSD), and 1-butanoyl-d-lysergic acid diethylamide (1B-LSD) were obtained 
from Synex Synthetics BV (Maastricht, The Netherlands) as the hemitartrate (2:1) salts.  
M100,907 and d-lysergic acid diethylamide (LSD) hemitartrate (2:1) were available from 
previous studies.  LSD-d3 was obtained from LGC Standards (Wesel, Germany).  For 
competitive binding and functional assays, test substances were dissolved in dimethyl sulfoxide.  
For studies in mice, ALD-52 was dissolved in isotonic saline and administered by the 
intraperitoneal (IP) route (5 mL/kg).  M100907 was dissolved in water containing 2% Tween-80 
and administered by the subcutaneous (SC) route (5 mL/kg).  For studies in rats, test substances 
were dissolved in isotonic saline and injected subcutaneously (1 mL/kg).     
 
2.3.  Binding Studies 
 
 A screening at 27 receptor binding sites was performed by the NIMH Psychoactive Drug 
Screening Program (NIMH PDSP).  LSD, ALD-52, 1P-LSD, and 1B-LSD were tested at 10 µM 
in competition assays against radioactive probe compounds; each primary binding assay was 
performed in quadruplicate.  Sites exhibiting >50% inhibition at 10 µM were tested in secondary 
assays at the identified receptor using 11 concentrations of the lysergamide, measured in 
triplicate, to generate competition binding isotherms.  Ki values were obtained from best-fit IC50 
values (derived from nonlinear regression of the binding isotherms) using the Cheng-Prusoff 
equation (Cheng and Prusoff 1973).  The experimental protocols are available from the NIMH 
PDSP website (Roth 2013). 
 
2.4.  5-HT2 Receptor Functional Assays 
 
 5-HT2 functional experiments (measuring Gq-mediated calcium flux) were performed 
with Flp-In T-REx 293 cells (Invitrogen, Carlsbad, CA, USA) expressing either human 5-HT2A 
(h5-HT2A), mouse 5-HT2A (m5-HT2A), human 5-HT2B (h5-HT2B) or human 5-HT2C INI (h5-
HT2C) receptor cDNA under the tetracycline repressor protein.  In the T-Rex system, receptor 
expression was induced with 2 ! g/mL tetracycline, and cells were plated into black 384 clear-
bottom, tissue culture plates in 40 ! L of DMEM containing 1% dialyzed foetal bovine serum 
(FBS) at a density of approximately 10,000 cells per well.  After approximately 20-24 hours, 
media was decanted and replaced with 20 ! L per well of drug buffer (HBSS, 20 mM HEPES, pH 
7.4) containing Fluo-4 Direct dye (Invitrogen) and incubated for 1 h at 37°C.  Test substances 
were diluted in drug buffer (HBSS, 20 mM HEPES, 0.1% bovine serum albumin, 0.01% 
ascorbic acid, pH 7.4).  Before the experiment, plates were allowed to equilibrate to room 
temperature and calcium flux was measured using a FLIPRTETRA (Molecular Devices, Sunnyvale, 
CA, USA). Plates were read for fluorescence initially for 10 seconds (1 read per second) to 
establish a baseline, and then stimulated with drug dilutions or buffer and read for an additional 
120 seconds.  Peak fluorescence in each well was normalized to maximum-fold increase over 
baseline.  Data were normalized to the maximum peak fold-over-basal fluorescence produced by 
5-HT (100%) and baseline fluorescence (0%).  Data were analyzed using the sigmoidal dose-
response function of Prism 5.0 (GraphPad Software, San Diego, CA, USA). 
 
2.5.  Head-Twitch Response Studies 
 
 The head-twitch response (HTR) was assessed using a head-mounted magnet and a 
magnetometer detection coil (Halberstadt and Geyer 2013,2014; Nichols et al. 2015).  Briefly, 
mice were anesthetized, a small incision was made in the scalp, and a small neodymium magnet 
was attached to the dorsal surface of the cranium using dental cement.  Following a one-week 
recovery period, HTR experiments were carried out in a well-lit room with at least 7 days 
between sessions to avoid carryover effects. Test compounds were injected immediately prior to 
testing.  Mice (n = 5/group) were injected with drug or vehicle and then HTR activity was 
recorded in a glass cylinder surrounded by a magnetometer coil for 30 min.  Coil voltage was 
low-pass filtered (2–10 kHz cutoff frequency), amplified, and digitized (20 kHz sampling rate) 
using a Powerlab/8SP with LabChart software ver. 7.3.2 (ADInstruments, Colorado Springs, CO, 
USA), then filtered off-line (40–200 Hz band-pass).  Head twitches were identified manually 
based on the following criteria: 1) sinusoidal wavelets; 2) evidence of at least three sequential 
head movements (usually exhibited as bipolar peaks) with frequency "  40 Hz; 3) amplitude 
exceeding the level of background noise; 4) duration < 0.15 s; and 5) stable coil voltage 
immediately preceding and following each response.  Head twitch counts were analyzed using 
one-way analyses of variance (ANOVA).  Post hoc pairwise comparisons between selected 
groups were performed using Tukey's studentized range method.  Significance was demonstrated 
by surpassing an #-level of 0.05.  Median effective doses (ED50 values) and 95% confidence 
intervals (95% CI) for HTR dose-response experiments were calculated by nonlinear regression 
using a Gaussian distribution (Prism 7.00, GraphPad Software, San Diego, CA, USA).   
 
2.6.  Biotransformation Studies  
 
 Rats (n = 5-6/group, 29 total) were treated with vehicle, ALD-52 (0.1 or 0.3 mg/kg), or 
1P-LSD (0.1 or 0.3 mg/kg).  The animals were anesthetized (isoflurane) and decapitated 15 min 
post-injection, and trunk blood was collected in cooled heparinized tubes.  Plasma was isolated 
by centrifugation and stored at –80°C. 
 2.6.1.  Sample preparation by solid-phase extraction.  Sample preparation was 
performed in accordance with Maurer et al. (2016) with minor modifications.  Ten µL of 
methanolic LSD-d3 (as internal standard, final plasma concentration 2 ng/mL) were added to 0.5 
mL of rat plasma, diluted with 2 mL of purified water, mixed for 15 s on a rotary shaker, and 
loaded on a HCX cartridge (130 mg, 3 mL; Biotage, Uppsala, Sweden) previously conditioned 
with 1 mL of methanol and 1 mL of purified water. After extraction, the cartridge was washed 
with 1 mL of purified water, 1 mL of 0.01 M aqueous hydrochloric acid, and 2 mL of methanol. 
Reduced pressure was applied until the cartridge was dry and the analytes were eluted with 1 mL 
of a freshly prepared mixture of methanol-aqueous ammonia (98:2, v/v) into a reaction tube. The 
eluate was evaporated to dryness under a stream of nitrogen at 70°C and the residue was 
dissolved in 50 µL of a mixture of 10 mM aqueous ammonium formate-acetonitrile (1:1, v/v) 
containing 0.1% formic acid.  The limit of detection (LOD) of the method was 2 ng/mL LSD. 
 2.6.2.  LC- ion trap MS instrumentation for LSD quantification.  Samples were 
analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) LXQ linear ion trap MS, 
coupled to a TF Accela ultra high performance LC (UHPLC) system consisting of a degasser, a 
quaternary pump, and an autosampler.  Gradient elution was performed on a TF Hypersil GOLD 
C18 column (100 mm  2.1 mm inner diameter, 1.9 ! m particle size).  The mobile phase 
consisted of 10 mM aqueous ammonium formate plus 0.1% formic acid (pH 3.4, eluent A) and 
acetonitrile plus 0.1% formic acid (eluent B). The flow rate was set to 0.5 mL/min and the 
following gradient was used: 0–2.0 min 2% B, 2.0–4.0 min to 80% B, 4.0–6.0 min hold 80% B, 
6.0–6.5 min to 90% B, 6.5–7.0 min hold 90% B, 7.0-10.0 min hold 80% B, 10.0-17.0 hold 2% B. 
Analyses were performed in a targeted acquisition mode with an inclusion list, where MS2 
spectra of given precursor ions (LSD and LSD-d3) were recorded. The injection volume was 10 
µL each.  The MS was equipped with a heated electrospray ionization II (HESI-II) source, other 
conditions were as follows: positive ionization mode; sheath gas, nitrogen at flow rate of 34 
arbitrary units (AU); auxiliary gas, nitrogen at flow rate of 11 AU; vaporizer temperature, 250 
°C; source voltage, 3.00 kV; ion transfer capillary temperature, 300 °C; capillary voltage, 38 V; 
tube lens voltage, 110 V; automatic gain control (AGC) target, 5,000 ions for MS2; data type, 
centroid; normalized collision energy, 35.0; wideband activation, enabled; isolation width, m/z 
1.5.  TF Xcalibur Qual Browser software version 2.0.7 was used for data evaluation and LSD 
concentration was determined comparing the peak areas of LSD and LSD-d3 within the same 
run. 
 2.6.3.  LC-high resolution MS/MS instrumentation for detection of metabolites.  
Analyses were performed in accordance to Wagmann et al. (2019).  A TF Dionex UltiMate 3000 
Rapid Separation (RS) UHPLC system with a quaternary UltiMate 3000 RS pump and an 
UltiMate 3000 RS autosampler was used, controlled by the TF Chromeleon software version 
6.80, and coupled to a TF Q-Exactive Plus equipped with a HESI-II source.  Mass calibration 
was performed prior to analysis according to the manufacturer’s recommendations using external 
mass calibration.  Gradient elution was performed on a TF Accucore PhenylHexyl column (100 
mm  2.1 mm inner diameter, 2.6 ! m particle size).  The mobile phases consisted of 2 mM 
aqueous ammonium formate containing formic acid (0.1%, v/v) and acetonitrile (1%, v/v, pH 3, 
eluent A) and 2 mM ammonium formate in acetonitrile/methanol (50:50, v/v) containing formic 
acid (0.1%, v/v) and water (1%, v/v, eluent B).  The gradient and flow rate were programmed as 
follows: 0–10 min 10% B to 50% B, 10–12 min hold 98% B, and 12–14 min hold 10% B, 
constantly at a flow rate of 0.5 mL/min. HESI-II source conditions were as follows: heater 
temperature, 438 °C; ion transfer capillary temperature, 269 °C; sheath gas, 53 AU; auxiliary 
gas, 14 AU; sweep gas, 3 AU; spray voltage, 3.50 kV, and S-lens RF level, 60.0. Mass 
spectrometric analysis was performed in positive full-scan mode and targeted MS2 mode using 
an inclusion list containing accurate masses of expected metabolites.  Pick others mode was 
activated to ensure the recording of MS2 spectra of precursor ions not in the inclusion list.  The 
settings for full-scan data acquisition were as follows: resolution, 35,000; AGC target, 1e6; 
maximum injection time (IT), 120 ms; scan range, m/z 100–700. The settings for the targeted 
MS2 were as follows: resolution, 17,500; AGC target, 2e5; maximum IT, 250 ms; isolation 
window, m/z 1.0; high-collision dissociation cell with stepped normalized collision energy 17.5, 




3.1.  Receptor binding studies 
 
 Table 1 shows the affinities of LSD and N1-acyl-substituted homologues for recombinant 
human 5 HT1A, 5 HT2A, and 5-HT2C receptors (labelled with [3H]8 OH DPAT, 
[3H]ketanserin, and [3H]mesulergine, respectively).  Consistent with previous studies (Nichols et 
al. 2002; Rickli et al. 2015; Nichols 2018), LSD has nanomolar affinity for 5 HT1A (Ki = 9.5 
nM), 5 HT2A (Ki = 14.7 nM), and 5 HT2C (Ki = 45.3 nM) receptors.  N1-Acyl substitution 
reduced the affinity of LSD for the 5-HT1A receptor and the magnitude of the effect was 
dependent on the length of the acyl group.  1B-LSD had 36-fold lower affinity (Ki = 345 nM) 
than LSD, 1P-LSD had 67-fold lower affinity (Ki = 637 nM), and ALD-52 had 111-fold lower 
affinity (Ki = 1,054 nM).  5-HT2A receptor affinity was also reduced by N1-acyl substitution.  
Substitution with an acetyl group or a propanoyl group on the indole nitrogen of LSD reduced 5-
HT2A receptor affinity more than tenfold (ALD-52: Ki = 174 nM; 1P-LSD: Ki = 196 nM), 
whereas the reduction in 5-HT2A affinity produced by a butanoyl group was closer to fivefold 
(1B-LSD: Ki = 87.7 nM).  In contrast to the effect on 5-HT1A and 5-HT2A receptor affinity, N1-
acyl substitution increased the affinity of LSD for the 5-HT2C receptor by approximately 2–4-
fold (see Table 1). 
  In addition to focusing on the interaction of N1-acyl-substituted LSD derivatives with 5-
HT1A and 5-HT2A/2C receptors, the binding affinity of 1B-LSD was determined for 24 other 
monoamine receptors (Table 2).  Based on the data previously reported for LSD (see Table 3), 
N1-butanoyl substitution appears to have a detrimental effect on binding to most of those sites.  
Compared to LSD, 1B-LSD has 10–100-fold lower affinity for most monoamine receptor 
subtypes.  However, there were a few exceptions.  In addition to the 5-HT2C receptor (see above), 
1B-LSD also retains high affinity for the 5-HT2B receptor.  In a study using [3H]LSD as the 
radioligand, LSD bound to the human 5-HT2B receptor with Ki = 3.7 nM (Wacker et al. 2013), 
which is very similar to the affinity of 1B-LSD in the present investigation (Ki = 3.5 nM). 
  
3.2.  Functional assays at selected serotonin receptors 
 
 Experiments also assessed whether ALD-52, 1P-LSD and 1B-LSD can activate 5-HT2A, 
5-HT2B, and 5-HT2C receptors by measuring Gq-mediated Ca2+ flux in HEK cells (Table 4).  As 
shown in Fig. 2, ALD-52 (EC50 = 38 nM; Emax = 25%), 1P-LSD (EC50 = 11 nM; Emax = 11%) and 
1B-LSD (EC50 = 85 nM; Emax = 23%) act as very weak partial agonists at the human 5-HT2A 
receptor compared to LSD (EC50 = 1.52 nM; Emax = 94%) when evaluated under similar 
experimental conditions.  ALD-52, 1P-LSD and 1B-LSD were also tested at the murine 5-HT2A 
receptor (Table 4); those compounds had slightly higher potency and efficacy at m5-HT2A 
compared to h5-HT2A.  Notably, ALD-52, 1P-LSD, and 1B-LSD showed no agonist activity at 
h5-HT2B and h5-HT2C (Table 4), despite showing relatively high affinity for those sites (Tables 1 
and 2), indicative of antagonist activity at these receptors.  By contrast, LSD acts as an agonist at 
recombinant h5-HT2B and h5-HT2C receptors, albeit with slightly lower potency compared to h5-
HT2A and m5-HT2A receptors (Table 4).  
 
3.3.  Head-twitch response 
 
 ALD-52 induced the HTR when tested in mice (F(4,20) = 16.74, p<0.0001; Fig. 3).  
Analysis of the dose-response data by nonlinear regression showed that ALD-52 induces the 
behavior with an ED50 = 297.2 nmol/kg (Table 5).  The effects of LSD, 1P-LSD, and 1B-LSD on 
HTR, assessed in previous studies using similar methods (Halberstadt and Geyer 2013; Brandt et 
al. 2016; Brandt et al. 2019), are included in Table 5 for comparison.  Interestingly, the rank 
order of potency of the four lysergamides is inversely proportional to the length of the 
substituent present on the indole nitrogen.  LSD, with an ED50 value of 132.8 nmol/kg 
(Halberstadt and Geyer 2013), is the most potent compound in this series; ALD-52 and 1P-LSD 
have about half and one-third of the potency of LSD, respectively, whereas 1B-LSD is even less 
potent, acting with ~14% of the potency of LSD.  An extra-sum-of-squares F-test confirmed that 
ALD-52 (F(1,22) = 12.08, p=0.0021) is less potent than LSD in mice; similar results were 
reported previously for 1P-LSD and 1B-LSD (Brandt et al. 2016; Brandt et al. 2019).  
Nevertheless, although the N1-acyl substituted derivatives are less potent than LSD, the HTR 
studies confirm these compounds are capable of activating 5-HT2A receptors in vivo with 
relatively high potency compared to many other hallucinogens (Klein et al. 2018; Halberstadt et 
al. 2019a; Halberstadt et al. 2019b). 
 A blockade experiment with the selective 5-HT2A antagonist M100,907 was performed to 
confirm that ALD-52 induces the HTR by activating the 5-HT2A receptor.  As was shown 
previously for 1P-LSD (Brandt et al. 2016), ALD-52 (0.3 mg/kg) did not induce head twitches in 
mice pretreated with 0.1 mg/kg M100,907 (t(8) = 7.65, p < 0.0001; Fig. 3).  
 
3.4.  Biotransformation of ALD-52 and 1P-LSD 
 
 To determine whether ALD-52 and 1P-LSD are metabolized to LSD, plasma samples 
were collected 15 minutes after SC administration of those compounds to rats.  LSD was 
quantified using LSD-d3 as an internal standard.  As shown in Table 6, the plasma samples 
contained high levels of LSD.  In comparison, according to Aghajanian and Bing (1964), plasma 
levels in humans peak at 9.5 ng/mL after intravenous administration of 2 µg/kg LSD.  Another 
study detected 4.5 ng/mL LSD in the plasma of participants who had ingested 200 µg of the drug 
(Dolder et al. 2016).  Similar levels have been reported in LSD intoxication cases (Smith and 
Robinson 1985).  Conversely, the peak plasma concentrations in three rats injected IP with 0.5 
mg/kg LSD (Nakahara et al. 1996) are compatible with our findings for 0.3 mg/kg ALD-52 and 
0.3 mg/kg 1P-LSD.  Higher plasma concentrations (>0.25 µg/mL) were detected in monkeys 
(Macaca mulatta) after i.v. administration of 0.2 mg/kg LSD (Axelrod et al. 1957).  It appears 
that ALD-52 and 1P-LSD are deacylated at roughly the same rate because rats treated with either 
compound had almost identical plasma levels of LSD.   
 In addition to LSD, the parent compounds were also detected in plasma, as well as 
several other metabolites (Table 7).  The biotransformation was almost identical with the pattern 
observed previously when ALD-52 and 1P-LSD were incubated with human liver homogenates 
(Wagmann et al. 2019).  Possible metabolic pathways for ALD-52 and 1P-LSD are shown in Fig. 
4.  Both ALD-52 and 1P-LSD were metabolized by N-deethylation and N6-demethylation; ALD-
52 was also hydroxylated to two phenolic metabolites.  As shown in Table 7, various metabolites 
of LSD were present in the plasma samples.  Dihydroxy-LSD is probably identical to 2-oxo-3-
hydroxy-LSD (O-H-LSD), which is believed to be the main metabolite of LSD in humans (Poch 
et al. 1999; Johansen and Jensen 2005; Favretto et al. 2007; Dolder et al. 2015; Steuer et al. 
2017).  N-Deethyl-LSD (lysergic acid monoethylamide, LAE-32) and N6-demethyl-LSD (nor-
LSD) have been identified as metabolites of LSD in rats (Niwaguchi et al. 1974; Siddik et al. 
1979b) and humans (Lim et al. 1988; Cai and Henion 1996; Canezin et al. 2001; Steuer et al. 
2017).  Rats and humans are also known to metabolize LSD to 13- and 14-hydroxy-LSD and to 
the corresponding glucuronides (Siddik et al. 1975,1979b,a; Canezin et al. 2001; Steuer et al. 
2017).  Hydroxy LSD isomers 1 and 2 are probably identical to 13- and 14-hydroxy-LSD but it 
was not possible to determine the position of the hydroxy groups based on fragmentation 
patterns.  The third hydroxy LSD isomer is probably lysergic acid ethyl-2-hydroxyethylamide 
(LEO), which was previously detected as a human metabolite (Cai and Henion 1996; Canezin et 
al. 2001; Dolder et al. 2018). 
 
4.  DISCUSSION 
 LSD is a prototypical hallucinogen.  Similar to LSD, derivatives containing an acyl 
substituent on the indole nitrogen are also potent psychedelic drugs.  ALD-52, one of the earliest 
members of this class, was evaluated in humans in several published trials (Rothlin 1957; 
Abramson 1959; Isbell et al. 1959; Malitz et al. 1960).  More recent additions include 1P-LSD 
and 1B-LSD, which have been marketed online as “legal” alternatives to LSD.  One unresolved 
question is whether ALD-52, 1P-LSD, and 1B-LSD are active agents or alternatively serve as 
pro-drugs for LSD.  Although substitution at the indole nitrogen generally has detrimental effects 
on the binding of ergolines to human and monkey 5-HT2A receptors (Johnson et al. 1993; 
Johnson et al. 1994), ALD-52, 1P-LSD and 1B-LSD are only slightly less potent than LSD in 
humans, indicating they may act as prodrugs.  Indeed, in the present studies, N1-acyl substitution 
reduced the affinity of LSD for most monoamine receptors, including 5-HT2A sites.  In addition, 
although LSD acts as an agonist at 5-HT2 subtypes, ALD-52, 1P-LSD, and 1B-LSD have low 
efficacy or act as antagonists when tested in Ca2+-mobilization assays.  Despite their weak 
activity at 5-HT2A, all three compounds are relatively potent in mice, inducing the HTR with 
~15% to ~50% of the molar potency of LSD.  In the biotransformation experiment, ALD-52 and 
1P-LSD were rapidly and efficiently metabolized to LSD, which likely explains why they are 
behaviorally active via the 5-HT2A receptor despite having very low agonist efficacy.  In 
summary, the present findings support the hypothesis that ALD-52, 1P-LSD, and 1B-LSD act as 
pro-drugs for LSD. 
 Consistent with published in vitro evidence (Brandt et al. 2016; Wagmann et al. 2019), 
ALD-52 and 1P-LSD were rapidly metabolized to LSD after administration to rats, supporting 
the prediction that the latter agent is the active species.  As far as we are aware, this is the first 
demonstration under controlled conditions that ergolines are metabolized by deacylation after in 
vivo administration.  The deacylation of 1P-LSD to LSD reported in this study is consistent with 
a recent report about an intoxication case (Grumann et al. 2019).  N1-Demethylation, by contrast, 
is a known route of biotransformation for ergolines.  For example, methysergide is metabolized 
to methylergometrine in humans (Tfelt-Hansen et al. 1985; Bredberg et al. 1986), rats (Bredberg 
and Paalzow 1990), and dogs (Muller-Schweinitzer and Tapparelli 1986).  Mesulergine has also 
been shown to undergo N1-demethylation to active metabolites (Enz et al. 1984).  Based on the 
level of LSD in plasma detected 15 min after administration of ALD-52 and 1P-LSD, it appears 
the N1-acyl group is rapidly hydrolyzed.  The rapid metabolism of ALD-52 and 1P-LSD likely 
explains why those compounds have roughly the same time-course as LSD in humans (Isbell et 
al. 1959) and mice (Brandt et al. 2016).  The plasma concentration of LSD in rats treated SC 
with 0.3 mg/kg of ALD-52 or 0.3 mg/kg 1P-LSD is actually slightly higher than was observed in 
a previous study where rats received a larger dose of LSD (0.5 mg/kg) by the IP route (Nakahara 
et al. 1996), indicating a large percentage of the total dose is metabolized to LSD. 
 LSD and N1-unsubstituted analogs have submicromolar affinity for a variety of 
serotonergic, dopaminergic, and adrenergic receptors (Nichols et al. 2002; Rickli et al. 2015; 
Halberstadt et al. 2019c).  The addition of an acyl group to the indole nitrogen of LSD reduces its 
affinity for most of those sites, including the 5-HT2A receptor.  Consistent with these findings, 
N1-alkyl substitution has also been shown to reduce the affinity of ergolines for the 5-HT2A 
receptor in humans and monkeys (Johnson et al. 1993), likely because the indole N-H requires a 
hydrogen bond with the sidechain of S2425.46.  Notably, in contrast to the effect on 5-HT2A 
affinity, N1-acyl substitution had little effect on the binding of LSD to 5-HT2B and 5-HT2C 
receptors, indicating different molecular interactions are involved when LSD binds to these 
receptors.  Based on the published crystal structure of LSD bound to 5-HT2B (Wacker et al. 
2017), the indole nitrogen engages the backbone oxygen of G2215.42, also present in the 5-HT2C 
receptor, instead of the proposed 5-HT2A S2425.46 residue, found deeper in the pocket. Crystal 
structures of other ergolines such as methylergonovine have shown that the indole N-H 
interaction with transmembrane (TM) 5 residue 5.46  is critical for agonist activation (McCorvy 
et al. 2018), whereby longer indole N1-alkyl chains on ALD-52, 1P-LSD, and 1B-LSD would 
sterically inhibit movement of TM5 for activation, thus acting as antagonists or very weak partial 
agonists at 5-HT2 receptors. 
 The present studies focused on the interaction of ALD-52, 1P-LSD, and 1B-LSD with the 
5-HT2A receptor, which is thought to be the primary molecular target of LSD and other 
serotonergic hallucinogens.  5-HT2A receptor antagonists such as ketanserin and risperidone can 
block the characteristic effects of LSD, psilocybin, and ayahuasca (a hallucinogenic decoction or 
tea containing N,N-dimethyltryptamine) (Vollenweider et al. 1998; Valle et al. 2016; 
Kraehenmann et al. 2017a; Kraehenmann et al. 2017b; Preller et al. 2017; Preller et al. 2018a).  
Although ALD-52, 1P-LSD, and 1B-LSD likely act as prodrugs for LSD, they do retain some 
affinity and efficacy at the 5-HT2A receptor, which makes it difficult to completely exclude the 
possibility that some of their in vivo effects occur because they interact directly with 5-HT 
receptors.  It seems unlikely, however, that direct receptor interactions play a role in the 
mechanism of action of ALD-52 and 1P-LSD.  First, ALD-52 and 1P-LSD have considerably 
lower affinity and functional potency compared to LSD at 5-HT2A, so they would have to 
compete with LSD for access to the receptor.  Although the extent to which LSD occupies 5-
HT2A binding sites in the brain has not been reported, 5-HT2A occupation levels range from 43% 
to 72% in subjects given 3-30 mg. p.o. doses of psilocybin (Madsen et al. 2019).  If LSD 
occupies the 5-HT2A receptor to a similar extent and is primarily responsible for the psychedelic 
effects produced by ALD-52 and 1P-LSD, then the binding of LSD may limit the ability of the 
parent compounds to interact with the 5-HT2A receptor.  Furthermore, LSD has a relatively long 
residence time at 5-HT2A and only slowly dissociates once it binds (Bennett and Aghajanian 
1974; Burris and Sanders-Bush 1992; Wacker et al. 2017), further reducing the likelihood that 
ALD-52 and 1P-LSD can occupy the receptor to an appreciable extent after in vivo 
administration. 
 ALD-52 induced the HTR in mice, as was found for 1P-LSD and 1B-LSD in previous 
studies (Brandt et al. 2016; Brandt et al. 2019).  Blockade studies with the selective antagonist 
M100,907 confirmed that the HTR induced by ALD-52 and 1P-LSD is mediated by the 5-HT2A 
receptor.  Although ALD-52, 1P-LSD, and 1B-LSD have submicromolar affinity for the 5-HT2A 
receptor, those molecules are probably not the active species in the HTR experiments.  The 
number of head twitches induced by hallucinogens depends on the particular compound being 
tested and is probably determined by their efficacy at the 5-HT2A receptor.  Specifically, 
according to Vickers et al. (2001), the magnitude of the HTR is correlated with 5-HT2A agonist 
efficacy.  Mice also emit head twitches spontaneously due to 5-HT2A receptor activation by 
serotonin (Dursun and Handley 1996).  Notably, the baseline level of head twitches can mask the 
response induced by very weak 5-HT2A receptor agonists in mice (unpublished observations).  
The magnitude of the HTR induced by the 1-acyl LSD derivatives, however, exceeds the 
baseline level of head twitches, which is not consistent with their very low efficacy at the 5-HT2A 
receptor.  Hence, LSD is likely the active species in the HTR experiments shown in Figure 3, 
although we cannot completely exclude the possibility that ALD-52 contributes to the response.  
 In addition to LSD, several other metabolites of ALD-52 and 1P-LSD were detected in 
rats.  The same metabolites were observed when ALD-52 and 1P-LSD were incubated with 
pooled human liver microsomes (Wagmann et al. 2019), indicating these compounds are 
probably metabolized in a similar manner when they are administered to humans.  Based on 
these findings, positive screening results for LSD or its metabolites should be interpreted with 
caution because these results may not always reflect LSD intake (which may be important in 
forensic cases where 1-acetylated lysergamides might not be controlled substances).  Although 
ALD-52 and 1P-LSD have several unique metabolites that are not detected after intake of LSD 
(Dolder et al. 2018; Wagmann et al. 2019), all of the unique metabolites of ALD-52 and 1P-LSD 
are likely susceptible to N1-deacylation, so their concentration in plasma and tissues may 
decrease to undetectable levels if there is a relatively long interval between intake and sample 
collection. 
 In summary, the hallucinogenic effects produced by ALD-52, 1P-LSD, and 1B-LSD are 
likely dependent on their metabolism to LSD.  To our knowledge, this analysis is the first to 
quantify the pharmacological properties and biotransformation of LSD derivatives containing an 
acyl group on the indole nitrogen.  Although the first human studies with ALD-52 were 
conducted in the late-1950s, virtually nothing has been published about its pharmacological 
properties.  The present studies therefore answer longstanding questions about the mechanism of 
action of ALD-52 and other N1-substituted LSD derivatives.  Nevertheless, clinical trials are 
required to understand the mechanism of action of these compounds in humans.  Given the high 
probability that additional N1-substituted LSD derivatives will appear in the future, these results 
provide important insights into the action of this class of ergoline hallucinogens. 
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Table 1.  Receptor binding data for lysergamides at cloned human 5-HT1A, 5-HT2A, and 5-HT2C receptors.






Table 2.  Receptor binding data for 1B-LSD 
Receptor Speciesa Radioligand Ki (nM) ± SEMb,c 
5-HT1B Human [3H]GR125743 1,463 ± 338 (3) 
5-HT1D Human [3H]GR125743   295 ± 77 (5) 
5-HT2B Human [3H]LSD       3.5 ± 0.6 (3) 
5-HT5a Human [3H]LSD   158 ± 42 (3) 
5-HT6 Human [3H]LSD 
5-HT7A Human [3H]LSD 
#1A Human [3H]prazosin >10,000c 
#1B Human [3H]prazosin >10,000c 
#1D Human [3H]prazosin >10,000c 
#2A Human [3H]rauwolscine   537 ± 85 (3) 
#2B Human [3H]rauwolscine 2,656 ± 741 (3) 
#2C Human [3H]rauwolscine   812 ± 267 (3) 
$1 Human (heart) [125I]pindolol >10,000c 
$2 Human [3H]CGP12177 >10,000c 
$3 Human [3H]CGP12177 >10,000c 
D1 Human [3H]SCH23390 1,167 ± 175 (3) 
D2 Human [3H]N-methylspiperone >10,000c 
D3 Human [3H]N-methylspiperone   352 ± 64 (3) 
D4 Human [3H]N-methylspiperone 2,271 ± 417 (3) 
D5 Human [3H]SCH23390 >10,000c 
H1 Human [3H]pyrilamine >10,000c 
H2 Human [3H]tiotidine   842 ± 201 (4) 
H3 Guinea pig [3H]#-methylhistamine >10,000c 
H4 Human [3H]histamine >10,000c 
aCloned receptors were used unless noted otherwise. 
bThe number of independent determinations (performed in triplicate) is indicated in parentheses. 
cValues of >10,000 nM are listed when there was <50% displacement at 10 μM in the primary binding assay.
  LSD ALD-52 1P-LSD 1B-LSD 
Receptor Radioligand Ki (nM) ± SEMa Ki (nM) ± SEMa Ki (nM) ± SEMa Ki (nM) ± SEMa 
5-HT1A [3H]8-OH-DPAT   9.5 ± 3.3 (3) 1,054 ± 367 (5) 637 ± 97 (4)   345 ± 118 (3) 
5-HT2A [3H]ketanserin 14.7 ± 4.2 (5)    174 ± 43 (3) 196 ± 19 (5)     87.7 ± 9.4 (3) 
5-HT2C [3H]mesulergine 45.3 ± 16.3 (3)      10.2 ± 3.5 (3)   13.0 ± 1.7 (3)     20.8 ± 3.4 (3) 
  607 ± 112 (3) 
  554 ± 158 (3) 
Table 3.  Previously published receptor binding data for LSD.
Receptor Speciesa Radioligand Ki  (nM) Reference 
5-HT1A Human [3H]8-OH-DPAT        3.0  (Rickli et al. 2015) 
 Human [3H]8-OH-DPAT        1.1  (Nichols et al. 2002) 
5-HT1B Human [3H]5-HT      12  (Peroutka 1994) 
 Rat [3H]GR125743        3.9  (Nichols et al. 2002) 
5-HT1D Human [3H]5-HT        2.4  (Peroutka 1994) 
5-HT2A Human [3H]ketanserin        4.2  (Rickli et al. 2015) 
 Rat [3H]ketanserin        5.2  (Egan et al. 2000) 
 Rat [3H]ketanserin      12  (Leonhardt et al. 1992) 
5-HT2B Human [3H]LSD        3.7  (Wacker et al. 2013) 
5-HT2C Human [3H]mesulergine      15  (Rickli et al. 2015) 
 Rat [3H]mesulergine      10  (Egan et al. 1998) 
5-HT5a Rat [3
5-HT6 Human [3
 Rat [3H]LSD        6.9  (Nichols et al. 2002) 
5-HT7A Rat [3
1A Human [3H]prazosin    670b (Rickli et al. 2015) 
2A Human [3H]rauwolscine      12  (Rickli et al. 2015) 
1 Rat [125
2 Rat [125
D1 Human [3H]SCH23390    310b (Rickli et al. 2015) 
 Rat [3
D2 Human [3H]spiperone      25 (Rickli et al. 2015) 
 Rat [3H]N-methylspiperone    120  (Nichols et al. 2002) 
D3 Human [3
 Rat [3H]N-methylspiperone      27  (Nichols et al. 2002) 
D4 Rat [3H]N
D5 Rat [3H]SCH23390    340  (Nichols et al. 2002) 
H1 Human [3 b (Rickli et al. 2015) 
3
aCloned receptors were used unless noted otherwise.   
bData were originally reported in µM; trailing zeroes were added to facilitate conversion to nM.
H]LSD        9.0  (Nichols et al. 2002) 
H]LSD        2.4  (Hirst et al. 2003) 
H]LSD        6.6  (Nichols et al. 2002) 
I]pindolol    140  (Nichols et al. 2002) 
I]pindolol    740  (Nichols et al. 2002) 
H]SCH23390    180 (Nichols et al. 2002) 
H]spiperone      96  (Rickli et al. 2015) 
-methylspiperone      56  (Nichols et al. 2002) 
H]pyrilamine 1,100
H]pyrilamine 1,540  (Nichols et al. 2002)  Rat (brain) [









Data represent the mean and SEM from between three and five independent experiments performed in triplicate. Emax is defined as percent 5-HT 
maximum response. N.A., No Activity 
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(7.45 ± 0.07) 25 ± 2 
11 
(7.99 ± 0.21) 11 ± 1 
85 
(7.07 ± 0.14) 23 ± 2 
1.52 
(8.82 ± 0.05) 94 ± 1 
0.38 
(9.42 ± 0.05) 100 
m5-HT2A 
12  
(7.94 ± 0.04) 29 ± 1 
28  
(7.55 ± 0.08) 23 ± 1 
45 
(7.35 ± 0.07) 35 ± 2 
4.25 
(8.37 ± 0.10) 86 ± 3 
0.54 
(9.27 ± 0.02) 100 
h5-HT2B N.A. N.A. N.A. N.A. N.A. N.A. 
15.3 
(7.81 ± 0.07) 78 ± 2 
0.53 
(9.27 ± 0.05) 100 
h5-HT2C N.A. N.A. N.A. N.A. N.A. N.A. 
35.1 
(7.46 ± 0.11) 82 ± 3 
0.25 
(9.60 ± 0.06) 100 
Table 5.  Summary of head twitch response (HTR) data for LSD and 1-acyl-substituted derivatives. 
Druga Dose 
(mg/kg) 
N HTR Counts 






(relative to LSD) 
LSDb    52.9 (38.9–72.0) 132.8 (97.6–180.7) 1 
       
1-Acetyl-LSD  0 5 6.4 ± 1.3 130.9 (93.9–182.3) 297.2 (213.2–413.9) 0.45 
 0.03 5 8.4 ± 1.6    
 0.1 5 12.6 ± 1.1    
 0.3 5 25.4 ± 3.2 *    
       
1-Propanoyl-LSDc  
1-Butanoyl-LSDd     457.6 (334.9–625.5) 976.7 (714.8–1335) 0.14 
*p<0.01 vs. vehicle control group (Tukey’s test) 
aAll of the compounds were hemitartrate (2:1) salts 
bData previously reported by Halberstadt and Geyer (2013) 
cData previously reported by Brandt et al. (2016) 
dData previously reported by Brandt et al. (2019). 
 






(LSD concentration, mean±SEM) (LSD concentration, mean±SEM) 
0.1 mg/kg    35.5±7.7 ng/mL 36.2±7.2 ng/mL 
0.3 mg/kg  103.8±9.7 ng/mL 98.8±17.3 ng/mL 
Plasma samples were collected from male Sprague-Dawley rats (n = 5-6/group) 15 min after SC administration of ALD-52
 
   158.9 (65.0–388.8) 349.6 (143.0–855.4) 0.38 
or 1P-LSD. 
Table 7.  Metabolites of ALD-52 and 1P-LSD that were detected in rats. 
 
 
Parent drug and metabolites detected 
Treatment Drug 
ALD-52 1P-LSD 
0.1 mg/kg 0.3 mg/kg 0.1 mg/kg 0.3 mg/kg 
ALD-52     
     ALD-52 + + - - 
     N  - - + + 25-DLA lyhteeD-
     N6  - - + + 25-DLA lyhtemeD-
     Hydroxy ALD-52 isomer 1 (indole ring) - + - - 
     Hydroxy ALD-52 isomer 2 (ethylamide function) + + - - 
1P-LSD 
     1P-LSD - - + + 
     N  + - - - DSL-P1 lyhteeD-
     N6  + + - - DSL-P1 lyhtemeD-
     N-Deethyl-N6-demethyl 1P-LSD 
LSD metabolites 
     N-Deethyl LSD (lysergic acid monoethylamide) 
     N6-Demethyl LSD (nor-LSD) + + + + 
     Hydroxy LSD isomer 1 (indole ring) 
     Hydroxy LSD isomer 2 (indole ring) 
     Hydroxy LSD isomer 3 (ethylamide function) 
     Dihydroxy LSD (2-oxo-3-OH-LSD) + + + + 
     Hydroxy LSD glucuronide (indole ring) + + - + 
Table S1.  Individual data points for the two panels in Figure 3. 
Experiment Drug treatment Head-twitch counts for the entire 30-min test sessions 
 11 ,7 ,6 ,5 ,3 elciheV 1
 21 ,01 ,01 ,7 ,3 25-DLA gk/gm 30.0 
 61 ,41 ,21 ,11 ,01 25-DLA gk/gm 1.0 
 43 ,23 ,22 ,02 ,91 25-DLA gk/gm 3.0 
 02 ,91 ,61 ,51 ,31 25-DLA gk/gm 1 
2 Vehicle + 0.3 mg/kg ALD-52 10, 17, 18, 19, 23 
 0.1 mg/kg M100907 + 0.3 mg/kg ALD-52 0, 0, 0, 0, 3 
 
- - - + 
+ + + + 
- - + + 
+ + + + 
- - + + 
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Figure 1.  Chemical structures of LSD and N1-substituted derivatives.  Structural changes in 
comparison to LSD are indicated in blue. 
 
Figure 2.  Agonist and antagonist potencies of N1-substituted LSD derivatives at the human 5-
HT2A (h5-HT2A) receptor.  Receptor activation was assessed using Ca2+ mobilization.  
Concentration-response curves are shown for 5-HT, LSD, ALD-52, 1P-LSD, and 1B-LSD.  
Antagonist assays were performed in the presence of 3 nM 5-HT.  Values are the mean ± SEM 
of between three and five independent experiments performed in triplicate. 
 
Figure 3.  Effect of ALD-52 on the head twitch response (HTR) in male C57BL/6J mice.  (Left 
panel) ALD-52 produces a dose-dependent increase in HTR counts.  Mice (n = 5/group, 25 total) 
were treated with ALD-52 and HTR was assessed for 30 min.  (Right panel) The HTR induced 
by ALD-52 is blocked by pretreatment with the selective 5-HT2A receptor antagonist M100,907.  
Mice (n = 5/group, 10 total) were pretreated with vehicle or 0.1 mg/kg M100907 and then treated 
with 0.3 mg/kg ALD-52.  Data are presented as group means ± SEM for the entire 30 min test 
sessions.  The individual data points for the two panels are included in Table S1.  *p < 0.01, 
significant difference from the vehicle control group. 
 
Figure 4.  Postulated metabolic pathways for ALD-52 and 1P-LSD after subcutaneous 
administration to Sprague-Dawley rats.  As indicated in the diagram, both ALD-52 and 1P-LSD 
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• N1-Substituted LSD derivatives such as ALD-52 are potent hallucinogens in humans 
• N1-Substitution markedly reduces the efficacy of LSD at the 5-HT2A receptor 
• ALD-52 and 1P-LSD are metabolized to LSD in rats  
• N1-Substituted LSD derivatives likely act as prodrugs 
